Paradigm Biocapital Advisors LP
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 14, 2026), Paradigm Biocapital Advisors LP reported 28 stock positions worth $5.3 billion. Its top holding was Revolution Medicines (RVMD) at 22.3% of the portfolio, followed by Nuvalent Class A (NUVL, 13.7%) and Edgewise Therapeutics (EWTX, 7.8%). Compared with Q1 2026, it opened 7 new positions, sold out of 14, added to 12 and reduced 7. The biggest buy was Spyre Therapeutics (SYRE, shares +96%) and the biggest sale an exit from Arcellx (ACLX).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001855655
- Portfolio Value
- $5.3B (Q2 2026)
- SEC Filing
- 0001855655-26-000014 ↗ filed Aug 14, 2026
Holdings Value
Holdings 28 stocks · $5.3B
| RVMD Revolution Medicines Inc. | 22.31% | 6,361,323 | $1.2B | Reduce -4.4% |
| NUVL Nuvalent Inc. Class A | 13.70% | 5,924,433 | $731.7M | Add +11.3% |
| EWTX Edgewise Therapeutics Inc. | 7.77% | 10,215,455 | $415.1M | Add +38.7% |
| GMAB Genmab A/S -SP ADR | 6.76% | 13,133,131 | $360.8M | Add +64.8% |
| SYRE Spyre Therapeutics Inc. | 6.38% | 3,840,778 | $341.0M | Add +96.2% |
| APGE Apogee Therapeutics Inc. | 3.92% | 1,576,385 | $209.2M | Add +16.9% |
| ORKA Oruka Therapeutics Inc. | 3.82% | 2,144,526 | $204.1M | Reduce -7.6% |
| TNGX Tango Therapeutics Inc. | 3.72% | 6,357,523 | $198.7M | Add +58.5% |
| BLTE Belite Bio Inc. - ADR | 3.55% | 1,232,877 | $189.8M | Add +10.6% |
| ERAS Erasca Inc. | 3.28% | 9,550,000 | $175.0M | Reduce -8.1% |
| TARS Tarsus Pharmaceuticals Inc. | 3.27% | 2,775,649 | $174.7M | Add +8.3% |
| ALNY Alnylam Pharmaceuticals Inc. | 2.71% | 480,000 | $144.5M | New |
| INSM Insmed Inc. | 2.65% | 1,325,977 | $141.4M | Add +5.7% |
| MBX MBX Biosciences Inc. | 2.59% | 2,508,015 | $138.4M | New |
| PCVX Vaxcyte Inc. | 2.32% | 2,127,852 | $123.7M | Reduce -55.6% |
| VRDN Viridian Therapeutics Inc. | 2.31% | 6,723,788 | $123.5M | Add +113.5% |
| OLMA Olema Pharmaceuticals Inc. | 2.03% | 8,670,576 | $108.5M | Add +8.1% |
| JBIO Jade Biosciences Inc. | 1.19% | 2,857,405 | $63.5M | New |
| TYRA Tyra Biosciences Inc. | 1.09% | 1,828,607 | $58.4M | Reduce -11.0% |
| ASMB Assembly Biosciences Inc. | 0.80% | 1,553,748 | $42.7M | Add +133.6% |
| EYPT Eyepoint Inc. | 0.77% | 2,890,397 | $41.3M | Reduce -8.0% |
| ACHV Achieve Life Sciences Inc. | 0.61% | 4,951,856 | $32.3M | New |
| VOR Vor Biopharma Inc. | 0.60% | 1,750,000 | $32.2M | No change |
| MPLT Maplight Therapeutics Inc. | 0.46% | 685,852 | $24.6M | New |
| KARD Kardigan Inc. | 0.40% | 900,000 | $21.5M | New |
| LXEO Lexeo Therapeutics Inc. | 0.36% | 4,175,382 | $19.4M | Reduce -32.5% |
| EDIT Editas Medicine Inc. | 0.34% | 5,586,625 | $18.1M | New |
| IVA Inventiva SA - ADR | 0.28% | 4,000,000 | $15.1M | No change |
Portfolio Sells Q1 2026 → Q2 2026
| ACLX Arcellx Inc. | Sold out | 0.00% | −13.55 |
| PCVX Vaxcyte Inc. | Reduce -55.6% | 2.32% | −3.37 |
| CNTA Centessa Pharmaceuticals Ltd. | Sold out | 0.00% | −2.90 |
| TERN Terns Pharmaceuticals Inc. | Sold out | 0.00% | −2.39 |
| CYTK Cytokinetics Inc. | Sold out | 0.00% | −1.99 |
| ABVX Abivax SA-ADR | Sold out | 0.00% | −1.76 |
| MAZE Maze Therapeutics Inc. | Sold out | 0.00% | −1.67 |
| SRRK Scholar Rock Holding Corp. | Sold out | 0.00% | −1.23 |
| MIRM Mirum Pharmaceuticals Inc. | Sold out | 0.00% | −1.18 |
| MANE Veradermics Inc. | Sold out | 0.00% | −0.68 |
| URGN Urogen Pharma Ltd. | Sold out | 0.00% | −0.63 |
| GPCR Structure Therapeutics Inc. | Sold out | 0.00% | −0.54 |
| TYRA Tyra Biosciences Inc. | Reduce -11.0% | 1.09% | −0.51 |
| ORIC Oric Pharmaceuticals Inc. | Sold out | 0.00% | −0.44 |
| LXEO Lexeo Therapeutics Inc. | Reduce -32.5% | 0.36% | −0.36 |
| ERAS Erasca Inc. | Reduce -8.1% | 3.28% | −0.16 |
| BBOT Bridgebio Oncology Therapeut | Sold out | 0.00% | −0.16 |
| KLRS Kalaris Therapeutics Inc. | Sold out | 0.00% | −0.08 |
| EYPT Eyepoint Inc. | Reduce -8.0% | 0.77% | −0.05 |
| ORKA Oruka Therapeutics Inc. | Reduce -7.6% | 3.82% | +1.50 |
| RVMD Revolution Medicines Inc. | Reduce -4.4% | 22.31% | +9.08 |
Portfolio Buys Q1 2026 → Q2 2026
| SYRE Spyre Therapeutics Inc. | Add +96.2% | 6.38% | +4.37 |
| EWTX Edgewise Therapeutics Inc. | Add +38.7% | 7.77% | +3.03 |
| ALNY Alnylam Pharmaceuticals Inc. | New | 2.71% | +2.71 |
| MBX MBX Biosciences Inc. | New | 2.59% | +2.59 |
| NUVL Nuvalent Inc. Class A | Add +11.3% | 13.70% | +2.55 |
| GMAB Genmab A/S -SP ADR | Add +64.8% | 6.76% | +2.39 |
| TNGX Tango Therapeutics Inc. | Add +58.5% | 3.72% | +2.01 |
| APGE Apogee Therapeutics Inc. | Add +16.9% | 3.92% | +1.60 |
| JBIO Jade Biosciences Inc. | New | 1.19% | +1.19 |
| VRDN Viridian Therapeutics Inc. | Add +113.5% | 2.31% | +1.05 |
| ACHV Achieve Life Sciences Inc. | New | 0.61% | +0.61 |
| MPLT Maplight Therapeutics Inc. | New | 0.46% | +0.46 |
| ASMB Assembly Biosciences Inc. | Add +133.6% | 0.80% | +0.42 |
| KARD Kardigan Inc. | New | 0.40% | +0.40 |
| EDIT Editas Medicine Inc. | New | 0.34% | +0.34 |
| BLTE Belite Bio Inc. - ADR | Add +10.6% | 3.55% | −0.08 |
| TARS Tarsus Pharmaceuticals Inc. | Add +8.3% | 3.27% | −0.40 |
| OLMA Olema Pharmaceuticals Inc. | Add +8.1% | 2.03% | −0.41 |
| INSM Insmed Inc. | Add +5.7% | 2.65% | −1.54 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 28 | $5.3B | RVMD, NUVL, EWTX, GMAB, SYRE |
| Q1 2026 | 35 | $4.9B | ACLX, RVMD, NUVL, PCVX, EWTX |
| Q4 2025 | 29 | $3.7B | NUVL, RVMD, ACLX, GMAB, TARS |
| Q3 2025 | 33 | $3.4B | NUVL, MRUS, ACLX, RVMD, TARS |
| Q2 2025 | 28 | $2.3B | NUVL, ACLX, MRUS, RVMD, TARS |
| Q1 2025 | 27 | $2.2B | NUVL, ACLX, RVMD, ONC, MRUS |
| Q4 2024 | 28 | $2.9B | NUVL, ACLX, ARGX, RVMD, JANX |
| Q3 2024 | 31 | $2.9B | NUVL, ACLX, ARGX, RVMD, CRNX |
| Q2 2024 | 35 | $2.6B | NUVL, ARGX, ACLX, RVMD, SRPT |
| Q1 2024 | 34 | $2.8B | NUVL, ACLX, ARGX, IRON, CRNX |